Feature|Videos|July 18, 2024
Navigating Challenges and Embracing Opportunities to Optimize mRNA Therapies
The discussion covers the challenges of optimizing mRNA therapies, including the diverse behaviors of mRNA in biological systems, as well as the opportunities presented by emerging mRNA technologies like circular and self-amplifying RNAs, and the role of regulators in ensuring quality control of these novel products.
Advertisement
Episodes in this series
The expert panel discussed the diversity of mRNA structures and behaviors, as well as the challenges and opportunities in optimizing mRNA design and synthesis. New directions in mRNA structure and chemistry, such as circular RNAs and self-amplifying RNAs, were also discussed, as well as the increasing complexity of mRNA therapeutics from a regulatory perspective.
Discussion Topics
- 00:07 - Challenges and opportunities in optimizing mRNA therapies
- 01:44 - Emerging mRNA technologies
- 04:20 - Role of regulators
Advertisement
Related to this article
mAbxience and Sandoz are targeting a $5.7 billion market with a proposed emicizumab biosimilar for hemophilia A.
Fayuvi scored 23.5 points higher than untreated peers on cognitive testing, backing the first-ever approval for a Sanfilippo syndrome A gene therapy.
Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
FDA compliance officers detailed 2026 guidance updates, online drug sale enforcement, and a first-of-its-kind AI-related warning letter at the PDA/FDA Joint Regulatory Conference.
Sanofi’s Jack Prior discusses how biopharmaceutical manufacturers can assess whether process data is ready for human and AI use, and the role of data quality, accessibility, governance, and AI in manufacturing.
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Dualitas will screen over 300,000 bispecific combinations for Roche, backing a deal worth up to $1 billion in immunology research.
FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.
Advertisement
Advertisement